Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Multinational, Double-blind, Placebo-controlled, Parallel-group Design Pilot Study to Estimate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamic Effects of Teriflunomide for 24 Weeks When Added to Treatment With Glatiramer Acetate in Subjects With Multiple Sclerosis
Brief Summary: The primary objective was to estimate the tolerability and safety of 2 doses of Teriflunomide administered once daily for 24 weeks, compared to placebo, in patients with multiple sclerosis \[MS\] with relapses who were on a stable dose of Glatiramer Acetate \[GA\].

The secondary objectives were:

* to estimate the effect of the 2 doses of Teriflunomide, compared to placebo, in combination with a stable dose of GA on Magnetic Resonance Imaging \[MRI\] parameters, relapse rate and patient-reported fatigue;
* to perform pharmacokinetic analyses of the 2 doses of teriflunomide in combination with a stable dose of GA.


Options:
A: Arm Label: Interferon beta-1a 44 mcg SC; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon beta-1a, Drug: Ocrelizumab-matching placebo | Arm Label: Ocrelizumab; Type: EXPERIMENTAL; Interventions: Drug: Ocrelizumab, Drug: Interferon beta-1a-matching placebo | Intervention Type: DRUG; Name: Interferon beta-1a; Assigned to Arm(s): Interferon beta-1a 44 mcg SC | Intervention Type: DRUG; Name: Ocrelizumab-matching placebo; Assigned to Arm(s): Interferon beta-1a 44 mcg SC | Intervention Type: DRUG; Name: Ocrelizumab; Assigned to Arm(s): Ocrelizumab | Intervention Type: DRUG; Name: Interferon beta-1a-matching placebo; Assigned to Arm(s): Ocrelizumab
B: Arm Label: fingolimod 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: fingolimod | Arm Label: fingolimod 0.25mg; Type: EXPERIMENTAL; Interventions: Drug: fingolimod | Arm Label: glatiramer acetate 20 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: glatiramer acetate | Intervention Type: DRUG; Name: fingolimod; Assigned to Arm(s): fingolimod 0.25mg, fingolimod 0.5 mg | Intervention Type: DRUG; Name: glatiramer acetate; Assigned to Arm(s): glatiramer acetate 20 mg
C: Arm Label: Placebo + GA; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for teriflunomide), Drug: Glatiramer Acetate (GA) | Arm Label: Teriflunomide 7 mg + GA; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide, Drug: Glatiramer Acetate (GA) | Arm Label: Teriflunomide 14 mg + GA; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide, Drug: Glatiramer Acetate (GA) | Intervention Type: DRUG; Name: Teriflunomide; Assigned to Arm(s): Teriflunomide 14 mg + GA, Teriflunomide 7 mg + GA | Intervention Type: DRUG; Name: Placebo (for teriflunomide); Assigned to Arm(s): Placebo + GA | Intervention Type: DRUG; Name: Glatiramer Acetate (GA); Assigned to Arm(s): Placebo + GA, Teriflunomide 14 mg + GA, Teriflunomide 7 mg + GA
D: Arm Label: methylprednisolone PO; Type: EXPERIMENTAL; Interventions: Drug: methylprednisolone PO | Arm Label: methylprednisolone IV; Type: ACTIVE_COMPARATOR; Interventions: Drug: methylprednisolone IV | Intervention Type: DRUG; Name: methylprednisolone PO; Assigned to Arm(s): methylprednisolone PO | Intervention Type: DRUG; Name: methylprednisolone IV; Assigned to Arm(s): methylprednisolone IV

Answer: C